百济神州的“成绩”有目共睹,但市场的反馈并不积极。当BD交易成为国内创新药爆发的核心催化因素,市场的偏好更倾向于大BD交易,业绩兑现的逻辑并不受市场重视。很显然,这是对已经盈利的创新药企业的“偏见”。近期,国内创新药“一哥”百济神州发布了2025年上半年业绩报告,财报显示,今年上半年,公司营业总收入175.18亿元,较上年同比上升46.03%;2025年半年度归属于母公司所有者的净利润4.50亿元...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.